Skip to content
OpenCapital
Get started

Gyre Therapeutics, Inc. GYRE Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

Revenue$37.2MBeat by $1.8M
EPS$0.04Miss by $0.02
Revenue estimate$35.4M
EPS estimate$0.06

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$26.5M
EPS estimate-$0.08

Financials

Q4 2025

Income statement

See full
Revenue$37.2M+33.4%
Gross profit$35.5M+32.8%
Operating income$118.0K-82.3%

Balance sheet

See full
Cash & equivalents$37.1M+214%
Total debt$939.0K-41.2%
Total equity$106.0M+67.5%
Total assets$166.1M+32.5%

Cash flow

See full
CapEx$144.0K—
Free cash flow-$5.8M-114%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$680.11M-34.5%
Enterprise value$643.98M-37.4%
P/S5.8×-4.0×

Profitability

See full
Gross margin95.4%-1.0pp
Operating margin9.9%-5.4pp
FCF margin-0.2%—

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio5.6×+2.3×

Segments

By product

See full
Contiva$2.5M—
Etorel$1.5M—

By segment

See full
Gyre Pharmaceuticals$37.2M+33.4%

Versus estimates

Revenue

Q1 2026$22.5MMiss by $9.1M
Q4 2025$37.2MBeat by $1.8M
Q3 2025$30.6MMiss by $5.7MQ2 2025$26.8MMiss by $7.5MQ1 2025$22.1MMiss by $6.6MQ4 2024$27.9MBeat by $4.4M

Diluted EPS

Q1 2026-$0.05Beat by $0.01
Q4 2025$0.04Miss by $0.02
Q3 2025$0.06Beat by $0.01Q2 2025$0.02Miss by $0.01Q1 2025$0.03In lineQ4 2024$0.01Miss by $0.03

Ask the moment Gyre Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Gyre Therapeutics, Inc. report Q4 2025 earnings?
Gyre Therapeutics, Inc. (GYRE) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Gyre Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Gyre Therapeutics, Inc. reported revenue of $37.2M and eps of $0.04 for Q4 2025.
Did Gyre Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $35.4M by $1.8M. EPS missed the consensus estimate of $0.06 by $0.02.
How did Gyre Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.4% from $27.9M a year earlier and eps grew 300.0% from $0.01.
Where can I find Gyre Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-102700) and the 10-K periodic report (0001193125-26-106251) directly on SEC EDGAR. The filing index links above go to sec.gov.